| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vidarabine | 96 | 2014 | 1341 | 4.960 |
Why?
|
| Cytarabine | 87 | 2013 | 1973 | 4.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 61 | 2014 | 2390 | 3.050 |
Why?
|
| Arabinonucleosides | 30 | 2013 | 437 | 3.010 |
Why?
|
| Deoxycytidine | 48 | 2014 | 1353 | 3.010 |
Why?
|
| Antimetabolites, Antineoplastic | 50 | 2014 | 1299 | 3.000 |
Why?
|
| Arabinonucleotides | 43 | 2008 | 71 | 2.210 |
Why?
|
| Leukemia | 43 | 2010 | 1635 | 2.100 |
Why?
|
| DNA Repair | 22 | 2012 | 1872 | 1.930 |
Why?
|
| Arabinofuranosylcytosine Triphosphate | 38 | 2007 | 75 | 1.870 |
Why?
|
| Antineoplastic Agents | 91 | 2012 | 14289 | 1.760 |
Why?
|
| Apoptosis | 41 | 2013 | 7591 | 1.750 |
Why?
|
| Cytosine | 5 | 2012 | 141 | 1.610 |
Why?
|
| DNA Replication | 18 | 2010 | 744 | 1.470 |
Why?
|
| DNA, Neoplasm | 30 | 2014 | 1910 | 1.450 |
Why?
|
| Vidarabine Phosphate | 21 | 2002 | 50 | 1.410 |
Why?
|
| Nucleosides | 8 | 2008 | 60 | 1.250 |
Why?
|
| Lymphocytes | 18 | 2010 | 1234 | 1.200 |
Why?
|
| DNA | 40 | 2011 | 2693 | 1.100 |
Why?
|
| G2 Phase | 5 | 2008 | 206 | 1.060 |
Why?
|
| Cell Survival | 25 | 2012 | 3045 | 1.010 |
Why?
|
| DNA Damage | 23 | 2012 | 1954 | 0.900 |
Why?
|
| Oxazoles | 4 | 2010 | 60 | 0.900 |
Why?
|
| DNA-Binding Proteins | 10 | 2012 | 4821 | 0.870 |
Why?
|
| RNA, Neoplasm | 6 | 2010 | 771 | 0.870 |
Why?
|
| Tumor Cells, Cultured | 43 | 2013 | 5395 | 0.850 |
Why?
|
| Leukemia, Myeloid, Acute | 46 | 2013 | 6915 | 0.840 |
Why?
|
| Leukemia, Myeloid | 13 | 2008 | 941 | 0.840 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 50 | 2013 | 15862 | 0.790 |
Why?
|
| Staurosporine | 7 | 2007 | 143 | 0.780 |
Why?
|
| Adenine Nucleotides | 19 | 2013 | 351 | 0.780 |
Why?
|
| S Phase | 7 | 2007 | 281 | 0.770 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2010 | 311 | 0.760 |
Why?
|
| Prodrugs | 7 | 2012 | 217 | 0.760 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2013 | 1823 | 0.750 |
Why?
|
| DNA-Activated Protein Kinase | 3 | 2011 | 76 | 0.700 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2012 | 316 | 0.680 |
Why?
|
| Thiazoles | 4 | 2010 | 726 | 0.660 |
Why?
|
| Cladribine | 11 | 2013 | 233 | 0.650 |
Why?
|
| Cell Cycle Proteins | 5 | 2011 | 2045 | 0.630 |
Why?
|
| Organoplatinum Compounds | 5 | 2013 | 702 | 0.620 |
Why?
|
| Alkaloids | 3 | 2002 | 75 | 0.620 |
Why?
|
| Deoxycytosine Nucleotides | 11 | 2001 | 32 | 0.610 |
Why?
|
| Cell Cycle | 20 | 2012 | 2084 | 0.610 |
Why?
|
| RNA Polymerase II | 3 | 2009 | 182 | 0.600 |
Why?
|
| Dose-Response Relationship, Drug | 40 | 2010 | 4938 | 0.590 |
Why?
|
| Ribonucleotide Reductases | 8 | 2003 | 51 | 0.590 |
Why?
|
| Drug Synergism | 18 | 2011 | 1313 | 0.590 |
Why?
|
| Phosphorylation | 25 | 2013 | 4804 | 0.590 |
Why?
|
| Cricetinae | 17 | 2012 | 706 | 0.580 |
Why?
|
| Endonucleases | 3 | 2011 | 178 | 0.570 |
Why?
|
| Phenanthrenes | 3 | 2011 | 42 | 0.570 |
Why?
|
| Blast Crisis | 8 | 2012 | 557 | 0.570 |
Why?
|
| Enzyme Inhibitors | 11 | 2007 | 1879 | 0.560 |
Why?
|
| Humans | 244 | 2014 | 261506 | 0.550 |
Why?
|
| Harringtonines | 3 | 2014 | 92 | 0.550 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2014 | 5178 | 0.530 |
Why?
|
| DNA Topoisomerases, Type II | 4 | 2011 | 116 | 0.520 |
Why?
|
| Drug Administration Schedule | 35 | 2013 | 3472 | 0.520 |
Why?
|
| Transcription, Genetic | 7 | 2011 | 3154 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 10 | 2011 | 1493 | 0.500 |
Why?
|
| Purines | 4 | 2010 | 273 | 0.470 |
Why?
|
| Cricetulus | 11 | 2012 | 205 | 0.470 |
Why?
|
| Purine Nucleosides | 7 | 2005 | 48 | 0.440 |
Why?
|
| CHO Cells | 6 | 2012 | 311 | 0.430 |
Why?
|
| Cell Line | 30 | 2012 | 5114 | 0.430 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 5 | 2002 | 43 | 0.420 |
Why?
|
| Adenosine Triphosphate | 15 | 2008 | 571 | 0.420 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2011 | 6 | 0.410 |
Why?
|
| Alanine | 2 | 2009 | 240 | 0.400 |
Why?
|
| RNA | 14 | 2005 | 1013 | 0.400 |
Why?
|
| Kinetics | 27 | 2005 | 2049 | 0.400 |
Why?
|
| Flavonoids | 3 | 2009 | 188 | 0.390 |
Why?
|
| Ataxia Telangiectasia | 1 | 2011 | 62 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2013 | 2796 | 0.380 |
Why?
|
| Leukemia, Lymphoid | 11 | 2005 | 276 | 0.380 |
Why?
|
| Cisplatin | 6 | 2003 | 2432 | 0.370 |
Why?
|
| Estradiol | 3 | 2003 | 748 | 0.370 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 | 2014 | 2527 | 0.370 |
Why?
|
| DNA Fragmentation | 4 | 2000 | 198 | 0.360 |
Why?
|
| Cytidine Triphosphate | 6 | 1995 | 9 | 0.360 |
Why?
|
| Mitochondria | 4 | 2008 | 1282 | 0.360 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2011 | 560 | 0.350 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 6 | 2011 | 275 | 0.350 |
Why?
|
| Coformycin | 9 | 1985 | 20 | 0.350 |
Why?
|
| Hematologic Neoplasms | 8 | 2013 | 1870 | 0.340 |
Why?
|
| Nucleoside Deaminases | 7 | 1985 | 33 | 0.340 |
Why?
|
| Infusions, Intravenous | 21 | 2008 | 1382 | 0.340 |
Why?
|
| Immunoblotting | 8 | 2009 | 886 | 0.330 |
Why?
|
| Alkylating Agents | 3 | 2007 | 78 | 0.320 |
Why?
|
| Chromatography, High Pressure Liquid | 14 | 2009 | 548 | 0.320 |
Why?
|
| Cell Line, Tumor | 19 | 2013 | 14551 | 0.320 |
Why?
|
| Animals | 65 | 2012 | 59536 | 0.320 |
Why?
|
| Oxides | 2 | 2006 | 211 | 0.320 |
Why?
|
| Arsenicals | 2 | 2006 | 201 | 0.310 |
Why?
|
| Guanosine Triphosphate | 11 | 2008 | 90 | 0.310 |
Why?
|
| Protein Kinases | 4 | 2007 | 874 | 0.310 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2010 | 713 | 0.310 |
Why?
|
| Phenanthridines | 1 | 2007 | 10 | 0.310 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2007 | 58 | 0.310 |
Why?
|
| Recombination, Genetic | 1 | 2010 | 613 | 0.310 |
Why?
|
| Nuclear Proteins | 3 | 2008 | 3343 | 0.300 |
Why?
|
| Ribonucleosides | 6 | 1984 | 40 | 0.300 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 5 | 2011 | 430 | 0.300 |
Why?
|
| DNA Repair Enzymes | 1 | 2008 | 237 | 0.300 |
Why?
|
| Signal Transduction | 9 | 2011 | 11965 | 0.300 |
Why?
|
| Cell Respiration | 1 | 2006 | 52 | 0.290 |
Why?
|
| Nucleotides | 8 | 1996 | 164 | 0.290 |
Why?
|
| DCMP Deaminase | 5 | 1996 | 10 | 0.290 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 1506 | 0.290 |
Why?
|
| Adenosine Deaminase Inhibitors | 7 | 1985 | 24 | 0.290 |
Why?
|
| Cells, Cultured | 17 | 2009 | 5637 | 0.290 |
Why?
|
| Ribonucleotides | 6 | 2013 | 52 | 0.290 |
Why?
|
| Piperidines | 3 | 2009 | 1035 | 0.280 |
Why?
|
| Leukemia, Experimental | 7 | 1994 | 78 | 0.280 |
Why?
|
| Thymine Nucleotides | 5 | 1992 | 17 | 0.280 |
Why?
|
| Histones | 3 | 2010 | 1466 | 0.280 |
Why?
|
| Cyclophosphamide | 7 | 2014 | 3001 | 0.280 |
Why?
|
| Lactams, Macrocyclic | 1 | 2006 | 90 | 0.270 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 852 | 0.270 |
Why?
|
| Benzoquinones | 1 | 2006 | 108 | 0.270 |
Why?
|
| Myelodysplastic Syndromes | 7 | 2012 | 2979 | 0.270 |
Why?
|
| HeLa Cells | 5 | 2010 | 1643 | 0.270 |
Why?
|
| Aged | 66 | 2014 | 70117 | 0.260 |
Why?
|
| Deoxyribonucleotides | 7 | 2001 | 21 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2008 | 3552 | 0.260 |
Why?
|
| Aphidicolin | 7 | 2003 | 30 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 2508 | 0.250 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2006 | 196 | 0.250 |
Why?
|
| Neoplasms | 16 | 2012 | 15193 | 0.250 |
Why?
|
| Checkpoint Kinase 1 | 4 | 2007 | 174 | 0.250 |
Why?
|
| Leukemia P388 | 5 | 1995 | 25 | 0.240 |
Why?
|
| Thymidine Kinase | 3 | 2005 | 193 | 0.240 |
Why?
|
| Pentostatin | 7 | 1996 | 119 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 2054 | 0.240 |
Why?
|
| Adult | 72 | 2013 | 77950 | 0.240 |
Why?
|
| Base Sequence | 14 | 2011 | 4917 | 0.240 |
Why?
|
| Drug Screening Assays, Antitumor | 7 | 2007 | 566 | 0.240 |
Why?
|
| Middle Aged | 74 | 2014 | 86204 | 0.240 |
Why?
|
| Glycolysis | 1 | 2006 | 519 | 0.240 |
Why?
|
| Stromal Cells | 4 | 2012 | 825 | 0.230 |
Why?
|
| Reactive Oxygen Species | 4 | 2012 | 987 | 0.230 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2008 | 854 | 0.230 |
Why?
|
| T-Lymphocytes | 10 | 2005 | 3869 | 0.230 |
Why?
|
| Guanine | 5 | 2010 | 151 | 0.230 |
Why?
|
| Deoxycytidine Kinase | 6 | 2007 | 27 | 0.230 |
Why?
|
| Acute Disease | 10 | 2009 | 2422 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 3639 | 0.220 |
Why?
|
| Time Factors | 23 | 2010 | 12926 | 0.210 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 2 | 2013 | 29 | 0.210 |
Why?
|
| cdc25 Phosphatases | 1 | 2002 | 97 | 0.210 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2002 | 129 | 0.210 |
Why?
|
| Clinical Trials as Topic | 13 | 2012 | 3719 | 0.210 |
Why?
|
| Maximum Tolerated Dose | 7 | 2013 | 1290 | 0.210 |
Why?
|
| Software | 1 | 2009 | 1321 | 0.210 |
Why?
|
| DNA Polymerase II | 4 | 2002 | 59 | 0.210 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 401 | 0.210 |
Why?
|
| Aged, 80 and over | 23 | 2013 | 29902 | 0.200 |
Why?
|
| Adenosine | 7 | 1991 | 289 | 0.200 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 1992 | 61 | 0.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2011 | 588 | 0.200 |
Why?
|
| Ubiquitin | 1 | 2003 | 344 | 0.200 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2001 | 7 | 0.200 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2012 | 503 | 0.200 |
Why?
|
| Ultraviolet Rays | 4 | 2009 | 575 | 0.200 |
Why?
|
| Female | 83 | 2014 | 141928 | 0.200 |
Why?
|
| Purine-Nucleoside Phosphorylase | 2 | 2005 | 46 | 0.190 |
Why?
|
| Caspases | 4 | 2009 | 661 | 0.190 |
Why?
|
| MicroRNAs | 3 | 2010 | 2947 | 0.190 |
Why?
|
| Molecular Sequence Data | 12 | 2011 | 6089 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 2 | 3 | 2010 | 249 | 0.190 |
Why?
|
| Amsacrine | 6 | 1994 | 61 | 0.190 |
Why?
|
| Repressor Proteins | 1 | 2008 | 1664 | 0.190 |
Why?
|
| Male | 74 | 2014 | 123000 | 0.190 |
Why?
|
| Adenine | 7 | 1987 | 631 | 0.190 |
Why?
|
| DNA Polymerase I | 3 | 2002 | 27 | 0.180 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2008 | 749 | 0.180 |
Why?
|
| Thymidine | 10 | 2005 | 155 | 0.180 |
Why?
|
| RNA, Antisense | 1 | 2000 | 69 | 0.180 |
Why?
|
| Substrate Specificity | 7 | 2010 | 549 | 0.180 |
Why?
|
| Drug Therapy, Combination | 8 | 2010 | 2315 | 0.180 |
Why?
|
| RNA, Messenger | 7 | 2011 | 6150 | 0.180 |
Why?
|
| HIV | 2 | 1992 | 229 | 0.180 |
Why?
|
| Cell Death | 4 | 2010 | 671 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2008 | 1039 | 0.180 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 223 | 0.180 |
Why?
|
| Drug Resistance | 8 | 2010 | 587 | 0.180 |
Why?
|
| Neoplastic Stem Cells | 3 | 2011 | 1443 | 0.180 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 266 | 0.180 |
Why?
|
| Salvage Therapy | 6 | 2014 | 2054 | 0.180 |
Why?
|
| Exodeoxyribonucleases | 2 | 1996 | 104 | 0.170 |
Why?
|
| Deoxyadenine Nucleotides | 5 | 2008 | 24 | 0.170 |
Why?
|
| Drug Design | 1 | 2001 | 375 | 0.170 |
Why?
|
| DNA Ligases | 2 | 1996 | 63 | 0.170 |
Why?
|
| Biotransformation | 7 | 1996 | 93 | 0.170 |
Why?
|
| Drug Evaluation | 16 | 1993 | 425 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2012 | 1544 | 0.170 |
Why?
|
| Protein Biosynthesis | 4 | 2014 | 889 | 0.160 |
Why?
|
| DNA-Directed DNA Polymerase | 4 | 1996 | 182 | 0.160 |
Why?
|
| In Vitro Techniques | 8 | 2008 | 1618 | 0.160 |
Why?
|
| Cell Division | 7 | 2003 | 2489 | 0.160 |
Why?
|
| DNA Adducts | 4 | 2014 | 210 | 0.160 |
Why?
|
| Genomics | 1 | 2009 | 2738 | 0.160 |
Why?
|
| K562 Cells | 3 | 2008 | 338 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 639 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 864 | 0.160 |
Why?
|
| Chromosome Aberrations | 5 | 2010 | 1960 | 0.150 |
Why?
|
| Structure-Activity Relationship | 5 | 2006 | 931 | 0.150 |
Why?
|
| Lymphoma | 5 | 2002 | 1467 | 0.150 |
Why?
|
| Enzyme Activation | 5 | 2006 | 1764 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 6 | 2014 | 5061 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2003 | 600 | 0.150 |
Why?
|
| Gene Silencing | 2 | 2011 | 837 | 0.150 |
Why?
|
| Chlorambucil | 1 | 1996 | 26 | 0.140 |
Why?
|
| Blotting, Western | 7 | 2013 | 3536 | 0.140 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 943 | 0.140 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1994 | 408 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2009 | 621 | 0.140 |
Why?
|
| Carbon-Nitrogen Ligases | 1 | 1995 | 2 | 0.140 |
Why?
|
| Tissue Distribution | 6 | 2014 | 875 | 0.140 |
Why?
|
| Drug Interactions | 6 | 2005 | 553 | 0.140 |
Why?
|
| Uridine | 7 | 1995 | 59 | 0.140 |
Why?
|
| Deoxyguanosine | 1 | 1995 | 37 | 0.130 |
Why?
|
| Recurrence | 13 | 2013 | 4758 | 0.130 |
Why?
|
| Hydroxyurea | 5 | 1998 | 204 | 0.130 |
Why?
|
| Antiviral Agents | 3 | 1992 | 1230 | 0.130 |
Why?
|
| Organophosphorus Compounds | 4 | 2009 | 101 | 0.130 |
Why?
|
| Deoxyuridine | 3 | 1993 | 5 | 0.130 |
Why?
|
| Proteins | 3 | 2000 | 1963 | 0.130 |
Why?
|
| Survival Analysis | 11 | 2014 | 9180 | 0.120 |
Why?
|
| Remission Induction | 16 | 2012 | 3569 | 0.120 |
Why?
|
| Mitoxantrone | 6 | 1996 | 216 | 0.120 |
Why?
|
| Zidovudine | 2 | 1992 | 40 | 0.120 |
Why?
|
| Acenaphthenes | 1 | 2013 | 6 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 289 | 0.120 |
Why?
|
| Thymidylate Synthase | 1 | 1993 | 53 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2001 | 709 | 0.120 |
Why?
|
| 3-Deazauridine | 4 | 1981 | 5 | 0.120 |
Why?
|
| Molecular Structure | 4 | 2009 | 515 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 3 | 2010 | 1487 | 0.120 |
Why?
|
| Tumor Stem Cell Assay | 3 | 2008 | 231 | 0.110 |
Why?
|
| Mice | 26 | 2011 | 34495 | 0.110 |
Why?
|
| 2-Chloroadenosine | 2 | 2010 | 37 | 0.110 |
Why?
|
| Models, Biological | 4 | 2014 | 3254 | 0.110 |
Why?
|
| Treatment Outcome | 29 | 2014 | 32848 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2009 | 2488 | 0.110 |
Why?
|
| CDC2 Protein Kinase | 2 | 2005 | 176 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2006 | 607 | 0.110 |
Why?
|
| Molecular Weight | 5 | 2012 | 629 | 0.110 |
Why?
|
| Half-Life | 9 | 2004 | 259 | 0.110 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 2 | 2011 | 119 | 0.110 |
Why?
|
| Glutathione | 2 | 2012 | 368 | 0.110 |
Why?
|
| Mitosis | 2 | 2005 | 615 | 0.100 |
Why?
|
| Cystine | 1 | 2012 | 34 | 0.100 |
Why?
|
| Flow Cytometry | 8 | 2012 | 3033 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 1390 | 0.100 |
Why?
|
| Oxidation-Reduction | 3 | 2008 | 717 | 0.100 |
Why?
|
| 5'-Nucleotidase | 1 | 2011 | 61 | 0.100 |
Why?
|
| Homologous Recombination | 1 | 2012 | 185 | 0.100 |
Why?
|
| Waldenstrom Macroglobulinemia | 4 | 1994 | 273 | 0.100 |
Why?
|
| Cytosol | 1 | 2011 | 238 | 0.100 |
Why?
|
| Guanosine | 2 | 1991 | 22 | 0.100 |
Why?
|
| Egtazic Acid | 3 | 1995 | 54 | 0.100 |
Why?
|
| Mitochondrial Membranes | 1 | 2010 | 58 | 0.100 |
Why?
|
| Uridine Triphosphate | 5 | 1993 | 19 | 0.090 |
Why?
|
| Adolescent | 18 | 2011 | 31252 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2013 | 260 | 0.090 |
Why?
|
| Sister Chromatid Exchange | 1 | 2010 | 45 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 1724 | 0.090 |
Why?
|
| RNA, Small Nuclear | 1 | 2010 | 57 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 1999 | 363 | 0.090 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 2 | 1989 | 30 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| Cell Communication | 2 | 2012 | 509 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 6207 | 0.090 |
Why?
|
| Nucleotide Deaminases | 1 | 1989 | 3 | 0.090 |
Why?
|
| Succinic Acid | 1 | 2010 | 23 | 0.090 |
Why?
|
| Fumarates | 1 | 2010 | 30 | 0.090 |
Why?
|
| DNA, Single-Stranded | 1 | 2010 | 106 | 0.090 |
Why?
|
| Caspase 9 | 2 | 2008 | 189 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2009 | 367 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 342 | 0.090 |
Why?
|
| Neoplasms, Experimental | 4 | 1999 | 750 | 0.090 |
Why?
|
| G1 Phase | 2 | 2006 | 285 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2010 | 64 | 0.090 |
Why?
|
| Glutamates | 1 | 2010 | 130 | 0.090 |
Why?
|
| HCT116 Cells | 1 | 2010 | 348 | 0.090 |
Why?
|
| Veratrum Alkaloids | 1 | 2009 | 32 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 6 | 2004 | 231 | 0.080 |
Why?
|
| Tumor Protein p73 | 1 | 2008 | 105 | 0.080 |
Why?
|
| MRE11 Homologue Protein | 1 | 2008 | 39 | 0.080 |
Why?
|
| Neutropenia | 2 | 2012 | 968 | 0.080 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 133 | 0.080 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2008 | 84 | 0.080 |
Why?
|
| Thrombocytopenia | 3 | 2012 | 846 | 0.080 |
Why?
|
| Polynucleotide Adenylyltransferase | 1 | 2008 | 10 | 0.080 |
Why?
|
| Caspase 3 | 3 | 2008 | 471 | 0.080 |
Why?
|
| Dioxolanes | 1 | 2008 | 41 | 0.080 |
Why?
|
| Isothiocyanates | 1 | 2008 | 44 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2010 | 641 | 0.080 |
Why?
|
| Core Binding Factors | 1 | 2008 | 112 | 0.080 |
Why?
|
| Biological Availability | 2 | 2002 | 214 | 0.080 |
Why?
|
| Hematologic Diseases | 2 | 1994 | 242 | 0.080 |
Why?
|
| Cyclin D1 | 1 | 2010 | 576 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2008 | 95 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 5159 | 0.080 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2008 | 43 | 0.080 |
Why?
|
| Tritium | 6 | 1993 | 200 | 0.080 |
Why?
|
| Polyadenylation | 1 | 2008 | 70 | 0.080 |
Why?
|
| Disease-Free Survival | 4 | 2012 | 10001 | 0.080 |
Why?
|
| Pneumonia | 2 | 2012 | 751 | 0.080 |
Why?
|
| Biometry | 1 | 2009 | 241 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2005 | 2074 | 0.080 |
Why?
|
| Cytosine Nucleotides | 1 | 1987 | 2 | 0.080 |
Why?
|
| Prognosis | 15 | 2014 | 21713 | 0.070 |
Why?
|
| Leukemia L1210 | 1 | 1987 | 54 | 0.070 |
Why?
|
| Bone Marrow | 8 | 2011 | 2358 | 0.070 |
Why?
|
| Radiation Tolerance | 3 | 1995 | 629 | 0.070 |
Why?
|
| Carbon Radioisotopes | 3 | 2005 | 116 | 0.070 |
Why?
|
| Cytidine Deaminase | 3 | 1995 | 83 | 0.070 |
Why?
|
| Ovary | 7 | 1986 | 668 | 0.070 |
Why?
|
| Phosphates | 3 | 2001 | 187 | 0.070 |
Why?
|
| Models, Chemical | 2 | 2004 | 186 | 0.070 |
Why?
|
| Anemia | 1 | 2012 | 689 | 0.070 |
Why?
|
| NAD | 1 | 2006 | 89 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2006 | 4971 | 0.070 |
Why?
|
| Hedgehog Proteins | 1 | 2009 | 424 | 0.070 |
Why?
|
| Drug Antagonism | 1 | 2006 | 32 | 0.070 |
Why?
|
| Clone Cells | 3 | 1995 | 555 | 0.070 |
Why?
|
| Multiprotein Complexes | 1 | 2008 | 395 | 0.070 |
Why?
|
| Superoxides | 2 | 2003 | 211 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2014 | 1094 | 0.070 |
Why?
|
| Pharmacokinetics | 1 | 2005 | 42 | 0.070 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 328 | 0.070 |
Why?
|
| Tetrahymena pyriformis | 2 | 1978 | 4 | 0.070 |
Why?
|
| Thymidine Monophosphate | 1 | 2005 | 2 | 0.070 |
Why?
|
| Cell Transformation, Viral | 1 | 1985 | 138 | 0.070 |
Why?
|
| Oncogene Protein v-akt | 1 | 2005 | 101 | 0.070 |
Why?
|
| Jurkat Cells | 1 | 2006 | 311 | 0.070 |
Why?
|
| Sarcoma, Experimental | 2 | 1996 | 68 | 0.070 |
Why?
|
| Rituximab | 4 | 2014 | 1528 | 0.070 |
Why?
|
| Simplexvirus | 1 | 1985 | 159 | 0.060 |
Why?
|
| Transfection | 1 | 2010 | 2944 | 0.060 |
Why?
|
| Methylation | 3 | 2011 | 597 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2006 | 311 | 0.060 |
Why?
|
| Chelating Agents | 2 | 1995 | 127 | 0.060 |
Why?
|
| Deoxycytidine Monophosphate | 2 | 1996 | 5 | 0.060 |
Why?
|
| Deoxyadenosines | 4 | 2008 | 42 | 0.060 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2005 | 89 | 0.060 |
Why?
|
| Cytidine | 3 | 1995 | 24 | 0.060 |
Why?
|
| Cell Proliferation | 4 | 2010 | 7226 | 0.060 |
Why?
|
| DNA Primers | 2 | 1997 | 1399 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2005 | 2803 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 301 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1995 | 226 | 0.060 |
Why?
|
| Chromosomes | 1 | 1985 | 244 | 0.060 |
Why?
|
| Thiosemicarbazones | 1 | 2003 | 23 | 0.060 |
Why?
|
| Phosphotransferases | 3 | 1989 | 84 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2008 | 310 | 0.060 |
Why?
|
| Adenosine Deaminase | 1 | 1984 | 94 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2010 | 992 | 0.060 |
Why?
|
| Rotenone | 1 | 2003 | 35 | 0.060 |
Why?
|
| Karyotyping | 4 | 2010 | 1022 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.060 |
Why?
|
| Biotin | 1 | 2003 | 69 | 0.060 |
Why?
|
| HL-60 Cells | 2 | 2002 | 302 | 0.060 |
Why?
|
| Deamination | 4 | 1990 | 13 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 324 | 0.060 |
Why?
|
| Pyrimidinones | 1 | 2005 | 314 | 0.060 |
Why?
|
| DNA, Viral | 1 | 1985 | 694 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2013 | 4549 | 0.060 |
Why?
|
| Caspase 8 | 1 | 2003 | 145 | 0.060 |
Why?
|
| Bromodeoxyuridine | 3 | 1995 | 139 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 150 | 0.060 |
Why?
|
| Free Radical Scavengers | 1 | 2003 | 80 | 0.060 |
Why?
|
| Floxuridine | 2 | 2000 | 38 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2003 | 227 | 0.050 |
Why?
|
| Survival Rate | 10 | 2010 | 12221 | 0.050 |
Why?
|
| Young Adult | 5 | 2013 | 21445 | 0.050 |
Why?
|
| Erythrocytes | 1 | 1984 | 339 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 507 | 0.050 |
Why?
|
| Arabinofuranosyluracil | 1 | 1992 | 42 | 0.050 |
Why?
|
| Adenosine Monophosphate | 4 | 1997 | 76 | 0.050 |
Why?
|
| fas Receptor | 1 | 2003 | 185 | 0.050 |
Why?
|
| Mutation | 4 | 2006 | 15179 | 0.050 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 1665 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2010 | 2022 | 0.050 |
Why?
|
| Annexin A5 | 1 | 2002 | 72 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2003 | 1944 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 388 | 0.050 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2002 | 97 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2010 | 1589 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2001 | 56 | 0.050 |
Why?
|
| Pyrroles | 1 | 2005 | 576 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2006 | 986 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 119 | 0.050 |
Why?
|
| Uracil Nucleotides | 1 | 1980 | 12 | 0.050 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2001 | 51 | 0.050 |
Why?
|
| Benzamides | 1 | 2006 | 1832 | 0.050 |
Why?
|
| Cyclin B | 1 | 2001 | 63 | 0.050 |
Why?
|
| Escherichia coli | 1 | 1987 | 1203 | 0.050 |
Why?
|
| Autoradiography | 4 | 1986 | 132 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2000 | 48 | 0.050 |
Why?
|
| Multiple Myeloma | 2 | 2010 | 2138 | 0.050 |
Why?
|
| Piperazines | 2 | 2006 | 2101 | 0.050 |
Why?
|
| U937 Cells | 1 | 2000 | 171 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2001 | 226 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2000 | 78 | 0.050 |
Why?
|
| Phosphorus Radioisotopes | 3 | 1992 | 44 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 1678 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 1489 | 0.050 |
Why?
|
| Follow-Up Studies | 7 | 2014 | 14889 | 0.050 |
Why?
|
| Cell Fusion | 2 | 1997 | 80 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2002 | 621 | 0.050 |
Why?
|
| Biological Transport | 2 | 2014 | 597 | 0.040 |
Why?
|
| Mammals | 1 | 2001 | 361 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2007 | 1616 | 0.040 |
Why?
|
| Ascites | 1 | 2000 | 198 | 0.040 |
Why?
|
| Pelvic Neoplasms | 1 | 2001 | 189 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 460 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 3230 | 0.040 |
Why?
|
| Carcinoma, Ehrlich Tumor | 4 | 1985 | 7 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2012 | 626 | 0.040 |
Why?
|
| Biological Transport, Active | 2 | 2014 | 131 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2001 | 434 | 0.040 |
Why?
|
| Child | 10 | 2011 | 29154 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 1073 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2008 | 2669 | 0.040 |
Why?
|
| Pentosyltransferases | 1 | 1978 | 25 | 0.040 |
Why?
|
| Dideoxynucleotides | 3 | 1992 | 8 | 0.040 |
Why?
|
| Templates, Genetic | 1 | 1997 | 86 | 0.040 |
Why?
|
| Base Composition | 1 | 1997 | 92 | 0.040 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1997 | 128 | 0.040 |
Why?
|
| Child, Preschool | 7 | 2011 | 16273 | 0.040 |
Why?
|
| Idarubicin | 3 | 2008 | 446 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 703 | 0.040 |
Why?
|
| Plasmids | 3 | 1997 | 837 | 0.040 |
Why?
|
| Prostaglandin Antagonists | 1 | 1996 | 6 | 0.040 |
Why?
|
| Uridine Monophosphate | 2 | 1992 | 18 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2004 | 604 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 1994 | 57 | 0.040 |
Why?
|
| Exodeoxyribonuclease V | 1 | 1996 | 28 | 0.040 |
Why?
|
| Cell-Free System | 2 | 2000 | 150 | 0.040 |
Why?
|
| Indomethacin | 1 | 1996 | 91 | 0.040 |
Why?
|
| Mice, Inbred DBA | 3 | 1983 | 110 | 0.040 |
Why?
|
| Pyridines | 1 | 2003 | 1244 | 0.040 |
Why?
|
| Nucleosomes | 1 | 1997 | 143 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2000 | 848 | 0.040 |
Why?
|
| Meningeal Neoplasms | 2 | 2000 | 441 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1997 | 251 | 0.030 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 1994 | 75 | 0.030 |
Why?
|
| Picolines | 1 | 1995 | 7 | 0.030 |
Why?
|
| Peptide Chain Elongation, Translational | 1 | 1995 | 6 | 0.030 |
Why?
|
| Pyrimidines | 2 | 2006 | 3518 | 0.030 |
Why?
|
| Mercaptopurine | 2 | 1994 | 130 | 0.030 |
Why?
|
| Dinucleoside Phosphates | 1 | 1995 | 19 | 0.030 |
Why?
|
| Thiourea | 1 | 1995 | 18 | 0.030 |
Why?
|
| Ligases | 1 | 1995 | 70 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 1993 | 600 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2014 | 573 | 0.030 |
Why?
|
| Deoxyguanine Nucleotides | 2 | 2005 | 21 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 76 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2010 | 366 | 0.030 |
Why?
|
| Binding, Competitive | 2 | 2001 | 300 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1995 | 153 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1995 | 129 | 0.030 |
Why?
|
| Chromosome Deletion | 2 | 1990 | 1005 | 0.030 |
Why?
|
| Mice, Inbred C3H | 4 | 1996 | 385 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 8873 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Temperature | 2 | 1991 | 506 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2004 | 665 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1997 | 406 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2001 | 882 | 0.030 |
Why?
|
| Topotecan | 3 | 2006 | 239 | 0.030 |
Why?
|
| Carcinogens | 1 | 1995 | 384 | 0.030 |
Why?
|
| HapMap Project | 1 | 2013 | 19 | 0.030 |
Why?
|
| Immunosuppressive Agents | 2 | 1998 | 1375 | 0.030 |
Why?
|
| Camptothecin | 2 | 1994 | 517 | 0.030 |
Why?
|
| Chromosome Inversion | 2 | 1994 | 182 | 0.030 |
Why?
|
| Puromycin | 1 | 1993 | 15 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 4757 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 7789 | 0.030 |
Why?
|
| Microchemistry | 1 | 1992 | 11 | 0.030 |
Why?
|
| Sea Urchins | 1 | 1973 | 26 | 0.030 |
Why?
|
| Ethidium | 1 | 1992 | 11 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 15694 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1993 | 97 | 0.030 |
Why?
|
| Azacitidine | 1 | 1999 | 1149 | 0.030 |
Why?
|
| Ovum | 1 | 1973 | 54 | 0.030 |
Why?
|
| DNA, Circular | 1 | 1992 | 34 | 0.030 |
Why?
|
| Binding Sites | 1 | 1997 | 2171 | 0.030 |
Why?
|
| Cell Extracts | 1 | 1992 | 62 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1993 | 145 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 2004 | 684 | 0.030 |
Why?
|
| Drug Approval | 1 | 2014 | 178 | 0.030 |
Why?
|
| Chromatin | 2 | 2010 | 942 | 0.030 |
Why?
|
| Disease Progression | 2 | 2014 | 6682 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 332 | 0.030 |
Why?
|
| Tumor Microenvironment | 2 | 2014 | 2864 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1992 | 48 | 0.030 |
Why?
|
| Intracellular Fluid | 1 | 1992 | 45 | 0.030 |
Why?
|
| Metaphase | 1 | 1992 | 107 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1998 | 1294 | 0.030 |
Why?
|
| Phosphonoacetic Acid | 2 | 1982 | 18 | 0.030 |
Why?
|
| Inactivation, Metabolic | 1 | 1991 | 37 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 1994 | 2292 | 0.030 |
Why?
|
| Gene Expression | 1 | 2000 | 3570 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 260 | 0.030 |
Why?
|
| Spinal Cord | 1 | 1995 | 690 | 0.030 |
Why?
|
| Aminoglycosides | 1 | 2012 | 220 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 191 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1995 | 850 | 0.020 |
Why?
|
| Poly A | 1 | 1991 | 87 | 0.020 |
Why?
|
| Guanosine Monophosphate | 1 | 1990 | 6 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2010 | 6009 | 0.020 |
Why?
|
| Aspartic Acid | 2 | 1982 | 126 | 0.020 |
Why?
|
| Cysteine | 1 | 2012 | 214 | 0.020 |
Why?
|
| Avian Myeloblastosis Virus | 1 | 1990 | 7 | 0.020 |
Why?
|
| Sarcoma | 1 | 2001 | 1725 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 1 | 1990 | 23 | 0.020 |
Why?
|
| DNA Polymerase III | 1 | 1990 | 31 | 0.020 |
Why?
|
| Nucleotide Mapping | 1 | 2010 | 24 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 130 | 0.020 |
Why?
|
| Drug Therapy | 1 | 1991 | 205 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 2008 | 4298 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1994 | 494 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1996 | 904 | 0.020 |
Why?
|
| Oligomycins | 1 | 2010 | 9 | 0.020 |
Why?
|
| Uncoupling Agents | 1 | 2010 | 15 | 0.020 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2010 | 28 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2014 | 652 | 0.020 |
Why?
|
| Cytidine Diphosphate | 1 | 1989 | 1 | 0.020 |
Why?
|
| Tetrahydrouridine | 1 | 1989 | 6 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1974 | 726 | 0.020 |
Why?
|
| Daunorubicin | 3 | 2002 | 301 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1991 | 261 | 0.020 |
Why?
|
| Phosphoribosyl Pyrophosphate | 2 | 1981 | 6 | 0.020 |
Why?
|
| Diterpenes | 1 | 1990 | 111 | 0.020 |
Why?
|
| Luciferases | 1 | 2011 | 445 | 0.020 |
Why?
|
| Ribavirin | 1 | 1991 | 178 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2010 | 102 | 0.020 |
Why?
|
| Citric Acid Cycle | 1 | 2010 | 86 | 0.020 |
Why?
|
| Tretinoin | 1 | 1992 | 623 | 0.020 |
Why?
|
| Mutagens | 1 | 1990 | 187 | 0.020 |
Why?
|
| Smoothened Receptor | 1 | 2009 | 52 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1992 | 362 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 508 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2010 | 627 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 905 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 1991 | 459 | 0.020 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1992 | 430 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 336 | 0.020 |
Why?
|
| Interphase | 2 | 1986 | 145 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2009 | 111 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2011 | 2086 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 1537 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 1084 | 0.020 |
Why?
|
| Pyrimidine Nucleotides | 2 | 1982 | 5 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2014 | 12873 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 2341 | 0.020 |
Why?
|
| Age Factors | 2 | 2010 | 5377 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 61 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 118 | 0.020 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2010 | 287 | 0.020 |
Why?
|
| Protein Binding | 2 | 2010 | 3438 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 866 | 0.020 |
Why?
|
| Risk Factors | 3 | 2012 | 17523 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 501 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 1328 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 4638 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 7222 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2009 | 270 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1973 | 1620 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 1869 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 974 | 0.020 |
Why?
|
| Phenotype | 2 | 2011 | 6295 | 0.020 |
Why?
|
| HIV-1 | 1 | 1992 | 653 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 2843 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 1979 | 521 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2013 | 13658 | 0.020 |
Why?
|
| Etoposide | 2 | 2002 | 870 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Estrogens | 1 | 2010 | 751 | 0.020 |
Why?
|
| Formates | 1 | 1986 | 8 | 0.020 |
Why?
|
| Genome, Human | 1 | 1995 | 1869 | 0.020 |
Why?
|
| Inosine | 1 | 1986 | 39 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 1489 | 0.020 |
Why?
|
| Dogs | 1 | 2008 | 1155 | 0.020 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1985 | 13 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 701 | 0.020 |
Why?
|
| Sulfones | 1 | 1987 | 143 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 869 | 0.020 |
Why?
|
| Bone Marrow Diseases | 3 | 1994 | 177 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 1519 | 0.020 |
Why?
|
| Metformin | 1 | 2010 | 378 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1986 | 207 | 0.020 |
Why?
|
| Benzoates | 1 | 1987 | 136 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 488 | 0.020 |
Why?
|
| Liver | 2 | 2003 | 2961 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 980 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 586 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2005 | 71 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1985 | 82 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 1985 | 67 | 0.020 |
Why?
|
| Y Chromosome | 1 | 1985 | 77 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2010 | 9244 | 0.020 |
Why?
|
| Permeability | 1 | 2005 | 167 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1323 | 0.020 |
Why?
|
| Intestinal Mucosa | 2 | 1982 | 1081 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 2 | 1998 | 543 | 0.020 |
Why?
|
| Celecoxib | 1 | 2005 | 200 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2232 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 1351 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 5112 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1985 | 362 | 0.010 |
Why?
|
| Rats | 2 | 1995 | 6086 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 4367 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2003 | 114 | 0.010 |
Why?
|
| Aspartate Carbamoyltransferase | 1 | 1982 | 6 | 0.010 |
Why?
|
| Free Radicals | 1 | 2003 | 62 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 3821 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 4988 | 0.010 |
Why?
|
| Combined Modality Therapy | 4 | 1999 | 8865 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 1547 | 0.010 |
Why?
|
| Chromatography, Gel | 2 | 1992 | 157 | 0.010 |
Why?
|
| Ku Autoantigen | 1 | 2001 | 79 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 465 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1992 | 568 | 0.010 |
Why?
|
| Mesocricetus | 1 | 1981 | 114 | 0.010 |
Why?
|
| Cell Count | 2 | 1997 | 508 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 4892 | 0.010 |
Why?
|
| Doxorubicin | 2 | 2001 | 3005 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3251 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2000 | 71 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2001 | 344 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1544 | 0.010 |
Why?
|
| Imidazoles | 1 | 2006 | 999 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2000 | 66 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2000 | 71 | 0.010 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2000 | 38 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 1391 | 0.010 |
Why?
|
| Calibration | 1 | 2000 | 337 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 1529 | 0.010 |
Why?
|
| United States | 2 | 2014 | 15433 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1985 | 1682 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1998 | 9 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 528 | 0.010 |
Why?
|
| Leukemia, T-Cell | 1 | 1998 | 87 | 0.010 |
Why?
|
| Cyclins | 1 | 2000 | 456 | 0.010 |
Why?
|
| Kidney | 1 | 1987 | 2146 | 0.010 |
Why?
|
| Uracil | 1 | 1978 | 64 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1982 | 6942 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1978 | 249 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7551 | 0.010 |
Why?
|
| Leukemia, B-Cell | 1 | 1998 | 117 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2000 | 369 | 0.010 |
Why?
|
| Xeroderma Pigmentosum | 1 | 1997 | 70 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1998 | 170 | 0.010 |
Why?
|
| Cytidine Monophosphate | 1 | 1997 | 2 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2000 | 374 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1998 | 170 | 0.010 |
Why?
|
| Infant | 2 | 2003 | 13310 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 6869 | 0.010 |
Why?
|
| High Mobility Group Proteins | 1 | 1997 | 59 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1998 | 314 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 5270 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1978 | 585 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1977 | 122 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1998 | 278 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3981 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 195 | 0.010 |
Why?
|
| Radiotherapy Dosage | 2 | 1994 | 3842 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 2 | 1993 | 1581 | 0.010 |
Why?
|
| Urinary Tract Infections | 1 | 2000 | 321 | 0.010 |
Why?
|
| Dihydroorotate Oxidase | 1 | 1995 | 1 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2005 | 1471 | 0.010 |
Why?
|
| Malondialdehyde | 1 | 1995 | 47 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1995 | 12 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2005 | 1823 | 0.010 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1975 | 31 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 1 | 1995 | 42 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1996 | 137 | 0.010 |
Why?
|
| Translocation, Genetic | 2 | 1994 | 1245 | 0.010 |
Why?
|
| Paresis | 1 | 1995 | 54 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 193 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1995 | 197 | 0.010 |
Why?
|
| Hindlimb | 1 | 1995 | 105 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1995 | 224 | 0.010 |
Why?
|
| Fever of Unknown Origin | 1 | 1995 | 63 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 6550 | 0.010 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1995 | 82 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 1998 | 577 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1996 | 486 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1994 | 149 | 0.010 |
Why?
|
| Arabinose | 1 | 1974 | 23 | 0.010 |
Why?
|
| Guanine Nucleotides | 1 | 1974 | 23 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1974 | 82 | 0.010 |
Why?
|
| DNA Probes | 1 | 1994 | 217 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1995 | 726 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1996 | 675 | 0.010 |
Why?
|
| Cognition | 1 | 2000 | 968 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1994 | 231 | 0.010 |
Why?
|
| Conjunctivitis | 1 | 1993 | 31 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1994 | 254 | 0.010 |
Why?
|
| Fertilization | 1 | 1973 | 56 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1974 | 243 | 0.010 |
Why?
|
| Brain Diseases | 2 | 1986 | 403 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1992 | 13 | 0.010 |
Why?
|
| Diphosphates | 1 | 1992 | 14 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1996 | 629 | 0.010 |
Why?
|
| DNA Ligase ATP | 1 | 1992 | 51 | 0.010 |
Why?
|
| Chromatography, Paper | 1 | 1971 | 6 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1979 | 4849 | 0.010 |
Why?
|
| Deoxyribonucleosides | 1 | 1971 | 3 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1971 | 26 | 0.010 |
Why?
|
| Meiosis | 1 | 1973 | 166 | 0.010 |
Why?
|
| Morphogenesis | 1 | 1973 | 337 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1996 | 1681 | 0.010 |
Why?
|
| Mycosis Fungoides | 1 | 1994 | 320 | 0.010 |
Why?
|
| Magnesium | 1 | 1971 | 160 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2010 | 10331 | 0.010 |
Why?
|
| Feedback | 1 | 1971 | 198 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1995 | 1014 | 0.010 |
Why?
|
| Carbon Isotopes | 1 | 1971 | 333 | 0.010 |
Why?
|
| Pancreatitis | 1 | 1993 | 267 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1993 | 467 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1994 | 544 | 0.010 |
Why?
|
| Colitis | 1 | 1993 | 340 | 0.010 |
Why?
|
| Bacteremia | 1 | 1995 | 689 | 0.010 |
Why?
|
| Biomarkers | 1 | 2001 | 5047 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1993 | 393 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1993 | 500 | 0.010 |
Why?
|
| Virus Replication | 1 | 1992 | 709 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1993 | 589 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2006 | 37905 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1994 | 1824 | 0.000 |
Why?
|
| Leukopenia | 1 | 1986 | 151 | 0.000 |
Why?
|
| Brain | 1 | 1979 | 4113 | 0.000 |
Why?
|
| Prednisone | 1 | 1987 | 984 | 0.000 |
Why?
|
| Methotrexate | 1 | 1987 | 999 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1984 | 225 | 0.000 |
Why?
|
| Vincristine | 1 | 1987 | 1511 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1986 | 712 | 0.000 |
Why?
|
| Lung Diseases | 1 | 1986 | 717 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 11538 | 0.000 |
Why?
|
| Paresthesia | 1 | 1980 | 33 | 0.000 |
Why?
|
| Lymphoma, Follicular | 1 | 1983 | 587 | 0.000 |
Why?
|
| Muscles | 1 | 1979 | 416 | 0.000 |
Why?
|
| Blood-Brain Barrier | 1 | 1979 | 238 | 0.000 |
Why?
|
| Skin Diseases | 1 | 1980 | 349 | 0.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1983 | 1664 | 0.000 |
Why?
|